2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Breast Neoplasms
107
Carcinoma, Renal Cell
74
Neoplasm Metastasis
48
Neoplasms
37
Neuroendocrine Tumors
35
Kidney Neoplasms
27
Recurrence
19
Tuberous Sclerosis
18
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
16
Triple Negative Breast Neoplasms
15
Lymphoma
15
Lymphoma, Mantle-Cell
14
Lymphoma, Large B-Cell, Diffuse
14
Head and Neck Neoplasms
14
Glioblastoma
14
Carcinoma, Hepatocellular
14
Colorectal Neoplasms
13
Stomach Neoplasms
12
Lung Neoplasms
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Hodgkin Disease
12
Brain Neoplasms
12
Sarcoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Glioma
11
Waldenstrom Macroglobulinemia
10
Lymphoma, Follicular
10
Carcinoma, Neuroendocrine
10
Interventions
pembrolizumab
3
Drug Therapy
3
Quality of Life
2
Proton Therapy
2
Immunotherapy
2
Blood Specimen Collection
2
ribociclib
1
palbociclib
1
napabucasin
1
fludarabine
1
epacadostat
1
bosutinib
1
amrubicin
1
alovudine
1
Tumor Burden
1
Sunitinib
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Plicamycin
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Histocompatibility Testing
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymus Neoplasms
×
Everolimus
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled